

Adherence 2017

JUNE 4-6, 2017 • MIAMI

Jointly sponsored by








ADHERENCE PROMOTION IN SUB-SAHARAN AFRICA

TRACY GLASS




Swiss Tropical and Public Health Institute Schweizerisches Tropen- und Public Health-Institut Institut Tropical et de Santé Publique Suisse Continuum of care in patients with unsuppressed viral load: data from rural Southern Africa - are we doing enough for children?





Lesotho – Kingdom in the Sky



ca. 2 mio habitants

ca. 160'000 AIDS-orphans

Adult HIV-prevalence 25%

Per capita income: 836 USD per year

Highest HIV transmission rate & lowest ART coverage

Average life-expectancy has dropped from 65 years in 1990's to 49 years in 2013

HIV testing coverage of up to 70.5%.


Only 32% of HIV+ adults were on ART in 2013


The 3rd 90: Viral Suppression Wiss TPH












Viral load platform

VisibleImpact







Reporting



Project Monitoring - Report 5

Note: Only confirmed labdata records with HIVL content are considered. Query period for lines 1,2,3,4,7 is by SpecimenTaken_TknDate,

From date	1. Jan 2016
To date	31. Dec 2016
Facility	All
VL Reason	All
Treatment Line	All

	All		Age 0-4		
	m+f	m	f	m	f
1 Total # of patients with VLs (VL not NULL)		1188	2368	9	11
2 Total # of patients with VLs ≥1000		125	207	1	7
3 Total # of patients with VLs between 20-999		238	403	4	2
4 Total # of patients with VLs <20		825	1758	4	2
5 Total # of patients switched from 1st line to 2nd line		7	16	0	0
6 Total # of patients switched from 2nd line to 3rd line		0	0	0	0
7 Overall # of labdata records (VL not NULL)		1342	2672	9	12

Viral load testing



N = 8,261 individuals tested

94% are seen in one of the 2 hospitals

On ART median 3.6 years (IQR: 1.5 – 6.4)


69% female

5.6% age<15 years

98% of tests for routine VL monitoring

9.2% of VL>1000 copies/ml Range across months 5 - 20%

41% had >1 VL done




ART regimens




ART regimen	Adult	Children			
3TC/EFV/TDF	66%	3%			
3TC/EFV/AZT	14%	31%			
3TC/NVP/AZT	7%	33%			
3TC/NVP/TDF	6%	<1%			
3TC/EFV/ABC	4%	13%			
3TC/ABC/LPV	<1%	10%			
3TC/AZT/LPV	<1%	7%			

Viral load



Elevated VL>1000 copies/ml — more common in children



Adherence



Nurses report if patient missed ≥ 1 dose of ART in the last 30 days

Only 2.6% reported non-adherence

In those reporting missed doses

VL>1000 copies/ml was more common

14.3% versus 9%, p=0.001

Follow-up



```
After having a first VL>1000
53% had a follow-up VL
after a median of 5 months (IQR: 3.6 – 6.4)
16% were done within 3 months
69% were done within 6 months
```

Children were more likely to have a follow-up 67% versus 51%, p=0.004

For those without a follow-up VL 55% were >6 months ago (no difference in children)

Follow-up VL




54% had a follow-up VL>1000 copies (treatment failure)
Failure rates were higher in children
61% versus 53%, p=0.3

If the follow-up VL was done >3 months after the first VL Rates slightly higher - 56% overall But children suffer more 68% versus 54%, p=0.04



Acknowledgments





Dr. Niklaus Labhardt

Fiona Vanobberghen Christian Heuss



Departement
Biomedizin
Basel

Prof. Thomas Klimkait

Lipontso Motaboli

Bienvenu Nsakala

Mabango Klaas

Christiane Fritz

Josephine Muhairwe

Karolin Pfeiffer

Jochen Ehmer



Dr. Niklaus Holbro Nico Schefer



Dr. Ravi Shankar Gupta Dr. Kyaw Thin Malebanye Lerotholi